Court Documents Show GlaxoSmithKline Knew – for 40 Years – Zantac Could Cause Cancer

Michael Nevradakis

Amid tens of thousands of lawsuits that are pending in state courts all across the U.S., a new report based on evidence discovered in these court cases reveals Big Pharma giant GlaxoSmithKline (GSK) had, for decades, concealed evidence showing that Zantac could cause cancer.

According to Bloomberg Businessweek, GSK — then known as Glaxo — had been aware of cancer- causing risks with ranitidine, the drug which was marketed as Zantac, even before it was approved by the U.S. Food and Drug Administration (FDA) in 1983. These warnings came from independent researchers but also from Glaxo scientists.

Within ve years, Zantac, used to treat or relieve heartburn, acid indigestion and gastric ulcers, became the world’s best-selling medicine and was one of the first to surpass $1 billion in annual sales, according to Reuters. GSK later sold the drug to Pfizer — and Zantac was then sold to Boehringer Ingelheim and nally Sano .

In 2019, an online pharmacy detected high levels of a potent carcinogen, NDMA, in Sano and its generic equivalents. This led to recalls, followed by a formal FDA withdrawal of the drug in 2020.

Latest articles

Byram W. Bridle … In response to a great question about a...
Vesanto Melina Soy has been the focus of considerable controversy. The roots...
Mark Messina … Isoflavones are classified as both phytoestrogens and selective estrogen...
BRMI … The lymphatic system lacks an organ that acts as a...
Jiacheng Huang et al. The extracellular matrix (ECM) is one of the...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!